Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.
|Articles|September 16, 2008
- May 31 2003
- Volume 10
- Issue 10
Government at Work?
Advertisement
We all know the federal government can spend money, but a look at real numbers and their correspondence to the gross domestic product (GDP) makes it seem all the more staggering. If only your pay as a physician could shoot up as handsomely as these figures.
Articles in this issue
about 18 years ago
Psychiatry in Finance Is a Sobering Thoughtabout 18 years ago
Add LTC Insurance to Your Estate Plansabout 18 years ago
Be a Guest at a Classic Hollywood Hotelabout 18 years ago
Get the Scoop on This Summer's US Openabout 18 years ago
Cinema Consults: TWO WEEKS NOTICEabout 18 years ago
In Memorium: Margaret Anderson (February 1, 1931-March 29, 2003)about 18 years ago
Incorporate Rules into Your Market Planabout 18 years ago
Don't Believe in Santa Claus Annuitiesabout 18 years ago
Weigh the Facts in Investing Tendenciesabout 18 years ago
When the Majority Agree, They're WrongAdvertisement
Related to this article
Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.
Approved US PFIC drugs treat pruritus. The researcher behind a therapy targeting BSEP on diagnosis, data, and what comes next.
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Hematology in September 2026: ASH raises ferritin thresholds for iron deficiency, plus marstacimab in hemophilia and curative SCD care.
Strong recommendations cover carvedilol or banding for varices, semiannual HCC surveillance, vaccines, and smoking cessation.
April Armstrong, MD, MPH, discusses 1-year RELIEVE-AD-PEDs data on rapid, sustained dupilumab disease control in adolescents with atopic dermatitis.
Physicians and patients cited perceived mild severity as the top reason for leaving HAE attacks untreated in a recent Adelphi survey.
Advertisement
Advertisement
Trending on HCPLive
1
The Benefits and Limits of Enlicitide, With Ninel Hovnanians, MD
2
Ritlecitinib Stabilizes Vitiligo in Tranquillo Trial, With Iltefat Hamzavi, MD
3
5 Gastroenterology Headlines You Missed in September 2026
4
From Injectable to Oral: Optimal Durable Clearance Across the IL-23 Class
5